- One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion
- Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology
- Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments
Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://nnw.fm/hDSmG). This is a big achievement for the company and is already making an impact in the pharmaceutical industry.
One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion. Also referred to as the first-pass effect or presystemic metabolism, this is an occurrence where whenever a patient takes a drug orally, it enters the liver and suffers extensive biotransformation to a level where its bioavailability or overall effectiveness is drastically reduced, ultimately showing subtherapeutic action (https://nnw.fm/SKRoL).
In the past, scientists and pharmaceutical companies have tried to address this by calculating the total quantity of the metabolized drug, with an equivalent amount of excess drug added to the oral formulation. Alternatively, they have tried to explore alternative routes of drug administration, specifically designed to bypass first-pass metabolism. Of the tried and tested workarounds to the issue, some have shown more promise than others. However, nothing comes close to Lexaria’s DehydraTECH.
Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of Colchicine, a drug with known SARS-CoV-2 anti-viral properties (https://nnw.fm/CBEmK).
DehydraTECH is applied by incorporating an intermediate step in the formulation and manufacturing of existing or orally ingestible and topical products. This is a crucial step that entails mixing the active ingredients as a delivery “payload” with specific fatty acids and infusing the mixture into a substrate material. The next step involves using a controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into end-product production across various dosage form factors.
From a commercial standpoint, Lexaria’s technology is proving to offer an additional layer that companies that offer consumer supplements, prescription, and non-prescription-based drugs, cannabis, and nicotine products can use to improve the effectiveness of both new and existing products. With over 50 pending patents in countries worldwide, along with 21 granted patents in countries of highest commercial potential such as the US, the EU, Japan and more, Lexaria understands the value of this technology and its usefulness, both to patients and pharmaceutical companies.
Gone are the days of having to calculate the total quantity of the metabolized drug once orally taken. DehydraTECH allows the body to bypass first-pass-liver processing, allowing for smaller doses and effective treatment for specific conditions and ailments. It is a tremendous milestone, not just for Lexaria but also for the medical industry. With what the company has achieved since 2014, it is evident that bigger and better things are to come.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.